Skin, Hair & Aesthetic
Peptides for Hair Growth: Evidence, Grades & Safety
A clinical, evidence-first ranking of the peptides marketed for hair regrowth — zinc-thymulin, copper peptides, biotinoyl tripeptide-1 (Procapil) and PTD-DBM — graded honestly, with human versus preclinical evidence kept strictly separate.
Zinc-ThymulinCopper PeptidesProcapilPTD-DBMAndrogenetic Alopecia
The quick verdict
Ranked strictly by the quality and directness of human evidence — only zinc-thymulin reaches a lower-bound Grade B; copper peptides, Procapil and PTD-DBM are all Grade C, and none reaches Grade A.
- Best overall
- Zinc-Thymulin — The only peptide with a dedicated human topical efficacy study of the peptide itself — a lower-bound Grade B on one open-label pilot plus human organ-culture mechanism. No peptide reaches Grade A.
- Best value
- Copper Peptides (GHK-Cu / Copper Tripeptide-1) — Best tissue-level evidence and a coherent mechanism, sold cheaply as a cosmetic serum — but the ex-vivo response is biphasic, so more is not better and there is no standalone human RCT.
- Best for Mechanistic promise / research interest
- PTD-DBM — The most elegant mechanism — a Wnt/β-catenin activator that blocks CXXC5 — with striking mouse regrowth, but zero human efficacy data. Compelling to watch, not to rely on.
How we evaluated
We ranked each peptide by the quality and directness of HUMAN evidence for hair regrowth in androgenetic alopecia, keeping human, ex-vivo, animal and manufacturer/combination data strictly separate. We applied a conservative evidence ramp (A = independent replicated human RCT/meta; B = lower-tier human such as small open-label pilots; C = preclinical, ex-vivo or confounded-combination only; D = anecdotal/marketing) and refused to inflate a preclinical signal to A or B. Delivery confounds (microneedling, micro-infusion, multi-active blends) were treated as reasons the peptide's solo effect cannot be credited. This is informational/editorial, not a buying guide.
- Directness of human evidence. Does a study test the peptide itself, applied on its own, in human subjects — or only ex-vivo tissue, animals, or multi-active combinations?
- Study quality. Randomization, blinding, placebo control, sample size and independent replication versus single-investigator, open-label, sponsor-run pilots.
- Mechanistic coherence in human tissue. Whether the proposed pathway (Wnt/β-catenin, VEGF/TGF-β1, anagen prolongation) is demonstrated in human follicles or scalp, not just cell lines or mice.
- Delivery realism. Whether reported benefit depended on microneedling/micro-infusion or nanocarriers, which confound attribution to the peptide alone.
- Safety & regulatory status. Tolerability data, contraindications (e.g. Wilson's disease for copper), and FDA/compounding status.
Rating scale: 1–5 stars, in half-star steps, reflecting the strength and directness of human evidence — NOT effect size or marketing claims. A high star rating here still means 'best of a weak field.'
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Zinc-Thymulin | B | 3.0 | Readers who want the single candidate with any dedicated human efficacy data — understanding it is lower-bound Grade B, not proof | Compounded prescription spray — varies by pharmacy |
| 2 | Copper Peptides (GHK-Cu / Copper Tripeptide-1, and AHK-Cu) | C | 2.5 | Readers wanting the best-mechanism, lowest-cost cosmetic option — with realistic, low-concentration expectations | Cosmetic serum — varies by brand |
| 3 | Biotinoyl Tripeptide-1 (Procapil) | C | 2.0 | Readers considering an off-the-shelf cosmetic complex who accept that the peptide's solo contribution is unproven | Cosmetic ingredient (~3% in finished formula) — varies by product |
| 4 | PTD-DBM | C | 1.5 | Readers following the science who understand this is mechanism-and-mouse only — with no human proof | Unapproved research chemical — no legitimate human product |
| 5 | The Proven Benchmark: Minoxidil & Finasteride (not peptides) | A | 4.5 | Anyone comparing peptides against what actually has proven human evidence for AGA | FDA-approved — OTC (minoxidil) / prescription (finasteride) |
Zinc-Thymulin
The only peptide with a dedicated human topical efficacy study of the peptide itself
Thymulin is a nine-amino-acid thymic peptide that is biologically active only when bound to zinc in equimolar ratio — hence 'zinc-thymulin.' It ranks first for a narrow but real reason: it is the single candidate here with a dedicated human topical efficacy study of the peptide applied on its own. The pivotal data is Vickers et al. 2017, a single-investigator pilot applying a water-based zinc-thymulin spray to 18 AGA subjects (17 men, one woman; ages 35–90; Norwood 2–7) over four to ten months, reporting increases in vellus and intermediate hair counts and no local or systemic adverse effects. Mechanistic backing comes from human hair-follicle organ culture, where thymulin prolonged anagen versus vehicle. But this is preliminary, not definitive: the pilot was open-label, unblinded, not placebo-controlled, not randomized, single-investigator and small — every feature that maximizes bias risk — with no independent replication and no RCT. An honest mechanistic wrinkle: in the organ-culture work thymulin actually reduced hair-shaft elongation even while extending the growth phase, so the net human effect is not as clean as marketing implies. It earns the top rank only because everything below it lacks any standalone human efficacy study.
Strengths
- The only peptide here with a dedicated human topical efficacy study of the peptide applied on its own
- Backed by human hair-follicle organ-culture mechanism (thymulin prolonged anagen versus vehicle)
- Well tolerated in the pilot — no local or systemic adverse effects reported over ~6 months
- Biologically rational: zinc is a recognized nutritional contributor to hair health
Weaknesses
- Pivotal study is a single open-label, unblinded, non-randomized, single-investigator pilot (n=18) with no placebo arm and no independent replication
- In organ culture, thymulin reduced hair-shaft elongation even while extending anagen — a mixed signal
- Sold as a compounded prescription topical that is not an FDA-approved finished drug
- Best for
- Readers who want the single candidate with any dedicated human efficacy data — understanding it is lower-bound Grade B, not proof
- Pricing
- Compounded prescription spray — varies by pharmacy
Source: Vickers et al., Hair Ther Transplant 2017 (open-label pilot, n=18)
Copper Peptides (GHK-Cu / Copper Tripeptide-1, and AHK-Cu)
Best tissue-level evidence and mechanism — but no standalone human RCT
GHK-Cu is the copper(II) complex of the endogenous tripeptide glycyl-L-histidyl-L-lysine (INCI Copper Tripeptide-1); AHK-Cu is the closely related alanyl-histidyl-lysine copper complex, and the two are sometimes used together in hair serums. Copper peptides have the best tissue-level evidence of any candidate: Pyo et al. 2007 cultured 240 isolated human scalp hair follicles from three donors plus dermal papilla cells and showed that AHK-Cu at very low molarity (10⁻¹²–10⁻⁹ M) stimulated follicle elongation and dermal-papilla-cell proliferation while suppressing apoptosis via Bcl-2/Bax. The mechanism is coherent and pro-anagen — raising VEGF for peri-follicular blood supply and lowering TGF-β1, the catagen-regression signal. Two important caveats keep this at Grade C. First, the response is biphasic: follicle growth was inhibited at higher concentrations, so more is not better and high-percentage marketing claims are biologically suspect. Second, there is no standalone, placebo-controlled human RCT; the only in-vivo human signal is a two-patient report that combined copper peptide with minoxidil and dutasteride, delivered by micro-infusion — the peptide's individual contribution cannot be isolated. It is the value pick because it is a cheap cosmetic with the best mechanism, provided expectations stay honest.
Strengths
- Best tissue-level evidence — actual elongation of cultured HUMAN scalp follicles ex vivo (Pyo et al. 2007)
- Coherent pro-anagen mechanism: VEGF up, TGF-β1 down, reduced dermal-papilla-cell apoptosis
- Widely available and inexpensive as a topical cosmetic serum
- Generally well tolerated at cosmetic concentrations
Weaknesses
- No standalone, placebo-controlled human RCT for hair growth — the only in-vivo human data combined it with minoxidil and dutasteride in just 2 patients
- Biphasic dose-response: higher concentrations INHIBITED follicle growth, so high-percentage products may be counterproductive
- Absolutely contraindicated in Wilson's disease and other copper-overload disorders; the 2007 data used AHK-Cu, a structural variant of the more common GHK-Cu
- Best for
- Readers wanting the best-mechanism, lowest-cost cosmetic option — with realistic, low-concentration expectations
- Pricing
- Cosmetic serum — varies by brand
Source: Pyo et al., Arch Pharm Res 2007 (ex-vivo human follicle culture, PMID 17703734)
Biotinoyl Tripeptide-1 (Procapil)
Human data exists only inside multi-ingredient combinations — never the isolated peptide
Biotinoyl (biotinyl) tripeptide-1 is biotin conjugated to the GHK tripeptide, and it is the peptide component of Procapil, a cosmetic complex that also contains oleanolic acid (a 5α-reductase inhibitor) and apigenin (a flavonoid said to improve microcirculation). The manufacturer's proposed mechanism is stimulation of laminin-5 and collagen IV at the hair bulb — the adhesion 'anchoring' the follicle in the dermis — plus extension of anagen, shown in cultured follicles. The problem for grading is attribution: every human study tests a multi-active product, never the isolated peptide. A 2025 open-label prospective trial randomized 48 AGA patients to a spray containing oleanolic acid, apigenin and biotinyl tripeptide-1 (with or without an added oral supplement) and reported improved trichoscopic measures over three months; an earlier six-month open-label study of a lotion combining biotinyl tripeptide-1 with oleanolic acid, apigenin, diaminopyrimidine oxide, adenosine, biotin and Ginkgo biloba in 56 patients reported significant increases in total and anagen hairs with no adverse events. Both are open-label, unblinded and un-placebo-controlled, and the strongest controlled efficacy figures come from the manufacturer's own cultured-follicle assays. Because the peptide's individual contribution is never isolated, it is best graded C. It is well tolerated as a topical cosmetic, but its solo effect on hair is unproven.
Strengths
- Has the most human study participants of any candidate here (though always in combination products)
- Coherent 'anchoring' mechanism — laminin-5/collagen IV at the hair bulb plus anagen extension
- Well tolerated as a topical cosmetic, with no adverse events reported over up to 6 months
- Widely formulated and available at a defined cosmetic use level (~3% Procapil)
Weaknesses
- Every human study is a multi-active formula — the peptide's individual contribution has never been isolated
- Independent studies are open-label without placebo; the strongest efficacy figures come from the manufacturer
- In-vitro 'grows as well as minoxidil' claims are sponsor cultured-follicle assays, not head-to-head clinical trials
- Best for
- Readers considering an off-the-shelf cosmetic complex who accept that the peptide's solo contribution is unproven
- Pricing
- Cosmetic ingredient (~3% in finished formula) — varies by product
Source: Voiculescu & Lupu, Cosmetics 2025;12:152 (open-label combination trial, n=48)
PTD-DBM
Elegant mechanism, compelling mouse data — zero human efficacy data
PTD-DBM ('Protein-Transduction-Domain–fused Dishevelled-Binding Motif') is a cell-penetrating competitor peptide that binds the PDZ domain of Dishevelled, displacing the Wnt brake CXXC5 and thereby reactivating Wnt/β-catenin signaling — the master 'build-a-follicle' pathway in hair morphogenesis. Mechanistically it is the most elegant candidate on this list. Discovered by Kang-Yell Choi's group at Yonsei University, topical PTD-DBM accelerated hair regrowth in mice and drove wound-induced hair-follicle neogenesis, with synergy when combined with valproic acid, and CXXC5-knockout mice showed accelerated regrowth confirming the target. Crucially, the mechanism's human relevance is real: CXXC5 is upregulated in the miniaturized follicles and arrector pili muscles of human balding scalps and mediates DHT-driven loss through the prostaglandin-D2 axis. But the honest verdict is stark: all efficacy data are in mice, from a single laboratory with no independent replication, and there is no published human efficacy study of any kind for PTD-DBM in hair loss as of 2026. Mouse follicle biology — especially neogenesis, which humans barely exhibit — differs importantly from chronic human AGA. It is sold as an unapproved 'research chemical' with no established human dose, protocol or safety data. It ranks last: fascinating to watch, not something to rely on.
Strengths
- The most elegant, targeted mechanism — reactivates Wnt/β-catenin by displacing the CXXC5 brake
- Striking mouse data: accelerated regrowth plus wound-induced follicle neogenesis, with CXXC5-knockout confirmation
- Human tissue relevance is verified — CXXC5 is upregulated in balding human scalps via the DHT–PGD2 axis
Weaknesses
- Zero human efficacy data — all results are in mice, from a single lab, with no independent replication
- Mouse follicle biology (especially neogenesis) differs importantly from chronic human AGA
- Sold as an unapproved 'research chemical' with no established human dose, protocol or safety data
- Best for
- Readers following the science who understand this is mechanism-and-mouse only — with no human proof
- Pricing
- Unapproved research chemical — no legitimate human product
Source: Lee et al., J Invest Dermatol 2017 (mouse + human tissue, PMID 28595998)
The Proven Benchmark: Minoxidil & Finasteride (not peptides)
The only FDA-approved AGA drugs — the honest reference every peptide is measured against
This entry is not a peptide, and that is precisely the point: any honest ranking of hair-growth peptides has to name the proven benchmark they are measured against and, so far, fall short of. Topical minoxidil and oral finasteride are the only FDA-approved pharmacologic treatments for androgenetic alopecia, with the HairMax LaserComb cleared as a device. Androgenetic alopecia is driven by dihydrotestosterone-induced follicular miniaturization: in genetically susceptible follicles, DHT progressively shortens the anagen growth phase, shrinks the follicle and converts terminal hairs to wispy vellus hairs. Minoxidil (a vasodilator that prolongs anagen) and finasteride (a 5α-reductase inhibitor that lowers DHT) attack that biology directly and are supported by large, replicated human randomized controlled trials — genuine Grade A evidence, the tier no peptide here reaches. From a functional, root-cause standpoint the appeal of peptides is that they aim to restore the follicle's own growth signaling, but the evidence-backed foundation remains addressing the DHT driver and follicle blood supply with these proven agents, correcting nutritional contributors (iron/ferritin, vitamin D, zinc), and ruling out thyroid and other systemic drivers. Peptides are best layered in as a hopeful adjunct — not a substitute for the basics.
Strengths
- The ONLY FDA-approved pharmacologic AGA treatments — minoxidil (topical) and finasteride (oral)
- Supported by large, replicated human randomized controlled trials — genuine Grade A evidence
- Attack AGA biology directly: minoxidil prolongs anagen; finasteride lowers DHT via 5α-reductase inhibition
Weaknesses
- Not peptides — included as the honest benchmark, not as a peptide recommendation
- Finasteride carries recognized sexual and mood side-effect risks in a minority of users; minoxidil requires indefinite continued use
- Neither is a cure — both manage, rather than reverse, the underlying genetic predisposition
- Best for
- Anyone comparing peptides against what actually has proven human evidence for AGA
- Pricing
- FDA-approved — OTC (minoxidil) / prescription (finasteride)
Source: Medscape/eMedicine, Androgenetic Alopecia Treatment & Management 2025
Frequently asked
Which peptide has the best evidence for hair growth?
On a strict reading, zinc-thymulin — it is the only candidate with a dedicated human topical efficacy study of the peptide applied on its own, though that study is a small, open-label, unblinded, single-investigator pilot in 18 subjects, so it earns only a lower-bound Grade B. Copper peptides (GHK-Cu / AHK-Cu) have the best tissue-level evidence — elongation of cultured human scalp follicles ex vivo — but no standalone human trial, keeping them at Grade C. No peptide reaches Grade A. The only FDA-approved AGA pharmacotherapies remain minoxidil and finasteride.
Does PTD-DBM actually regrow hair in people?
Unknown — there is no human efficacy data of any kind for PTD-DBM in hair loss as of 2026. The impressive regrowth and wound-induced neogenesis results are all in mice, from a single laboratory, with no independent replication. The mechanism is genuinely elegant: PTD-DBM displaces the Wnt brake CXXC5 from Dishevelled, reactivating Wnt/β-catenin signaling, and CXXC5 is verifiably upregulated in the miniaturized follicles of human balding scalps. But a real mechanism in human tissue is a reason to hypothesize benefit, not proof of clinical effect — and mouse follicle biology, especially neogenesis, differs importantly from chronic human AGA.
Are copper peptides as good as minoxidil for hair?
Not established in humans. Copper peptides stimulate cultured human follicles ex vivo and have a coherent pro-anagen mechanism, but no head-to-head controlled human trial versus minoxidil exists. The only in-vivo human signal comes from a two-patient report that combined copper peptide with both minoxidil and dutasteride and delivered them by micro-infusion, so the peptide's solo effect cannot be isolated. There is also a crucial dosing nuance: the ex-vivo response is biphasic, with follicle elongation stimulated at very low concentrations but inhibited at higher ones. More is not better, which makes high-percentage marketing claims biologically suspect.
Why do hair-peptide studies keep using microneedling or micro-infusion?
Because delivery is the bottleneck. Most of these peptides barely cross the intact stratum corneum to reach the dermal papilla through normal topical application. Microneedling and micro-infusion create physical channels that carry actives down to the follicle, which is why the larger and more impressive human numbers in the literature come from delivery-enhanced approaches. The catch is that those same techniques confound the results: when a peptide is micro-infused alongside minoxidil and dutasteride, any regrowth cannot be credited to the peptide alone. Delivery enhancement is both why the numbers look good and why they are hard to attribute to the peptide itself.
Are any of these hair peptides FDA-approved or safe to inject?
No peptide is FDA-approved for hair loss or hair growth. The only FDA-approved AGA drugs are topical minoxidil and oral finasteride, with the HairMax LaserComb cleared as a device. Copper tripeptide-1 and biotinoyl tripeptide-1 are regulated as cosmetics; zinc-thymulin is a pharmacy-compounded topical, not an FDA-approved finished drug; PTD-DBM has no approved status anywhere. Injectable or intradermal versions sold 'for research' carry the real risks of unregulated products — unknown purity and sterility, injection-site infection — and no controlled human efficacy data for hair. Copper peptides are absolutely contraindicated in Wilson's disease and other copper-overload disorders.
Can peptides replace minoxidil and finasteride?
No. From a functional, root-cause standpoint peptides are a plausible adjunct aimed at restoring the follicle's own growth signaling, but they are not a substitute for the evidence-backed basics. Androgenetic alopecia is driven by DHT-induced follicular miniaturization, and the proven foundation remains addressing that driver and the follicle's blood supply with minoxidil, plus finasteride or dutasteride where appropriate. Correcting nutritional contributors such as iron/ferritin, vitamin D and zinc is directly relevant — thymulin is inert without zinc. Peptides are best layered in as a hopeful complement, not a replacement, until a large independent human RCT for any of them actually reports.